BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 37370246)

  • 1. LncRNA ITGB2-AS1 promotes cisplatin resistance of non-small cell lung cancer by inhibiting ferroptosis via activating the FOSL2/NAMPT axis.
    Chen H; Wang L; Liu J; Wan Z; Zhou L; Liao H; Wan R
    Cancer Biol Ther; 2023 Dec; 24(1):2223377. PubMed ID: 37370246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propofol decreases cisplatin resistance of non-small cell lung cancer by inducing GPX4-mediated ferroptosis through the miR-744-5p/miR-615-3p axis.
    Han B; Liu Y; Zhang Q; Liang L
    J Proteomics; 2023 Mar; 274():104777. PubMed ID: 36427803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA ACTA2-AS1 inhibits the cisplatin resistance of non-small cell lung cancer cells through inhibiting autophagy by suppressing TSC2.
    Liu X; Zhang X; Du S
    Cell Cycle; 2022 Feb; 21(4):368-378. PubMed ID: 34985374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
    Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
    Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer.
    Huang Y; Ni R; Wang J; Liu Y
    Biomed Pharmacother; 2019 Jan; 109():1851-1859. PubMed ID: 30551440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
    He W; Zhang Y; Xia S
    Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long Noncoding RNA FGD5-AS1 Knockdown Decrease Viability, Migration, and Invasion of Non-Small Cell Lung Cancer (NSCLC) Cells by Regulating the MicroRNA-944/MACC1 Axis.
    Lv J; Li Q; Ma R; Wang Z; Yu Y; Liu H; Miao Y; Jiang S
    Technol Cancer Res Treat; 2021; 20():1533033821990090. PubMed ID: 33550920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
    Wang L; Shang X; Feng Q
    Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
    Fu J; Cai H; Wu Y; Fang S; Wang D
    Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA NCK1-AS1 promotes non-small cell lung cancer progression via regulating miR-512-5p/p21 axis.
    Luo X; Zhou J; Quan L; Liang Y; Huang P; Chen F; Liu S
    Pathol Res Pract; 2020 Nov; 216(11):153157. PubMed ID: 32858372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SNHG14 silencing suppresses the progression and promotes cisplatin sensitivity in non-small cell lung cancer.
    Jiao P; Hou J; Yao M; Wu J; Ren G
    Biomed Pharmacother; 2019 Sep; 117():109164. PubMed ID: 31252267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing lncRNA SLC16A1-AS1 Induced Ferroptosis in Renal Cell Carcinoma Through miR-143-3p/SLC7A11 Signaling.
    Li YZ; Zhu HC; Du Y; Zhao HC; Wang L
    Technol Cancer Res Treat; 2022; 21():15330338221077803. PubMed ID: 35167383
    [No Abstract]   [Full Text] [Related]  

  • 15. DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis.
    Zhao X; Wang J; Zhu R; Zhang J; Zhang Y
    Sci Rep; 2021 Oct; 11(1):21014. PubMed ID: 34697393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
    Shen Q; Xu Z; Xu S
    Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly expressed lncRNA FOXD3-AS1 promotes non-small cell lung cancer progression via regulating miR-127-3p/mediator complex subunit 28 axis.
    Zeng ZL; Zhu HK; He LF; Xu X; Xie A; Zheng EK; Ni JJ; Liu JT; Zhao GF
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2525-2538. PubMed ID: 32196603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long noncoding RNA regulatory factor X3- antisense RNA 1 promotes non-small cell lung cancer via the microRNA-577/signal transducer and activator of transcription 3 axis.
    Hu Y; Zhao Z; Jin G; Guo J; Nan F; Hu X; Hu Y; Han Q
    Bioengineered; 2022 Apr; 13(4):10749-10764. PubMed ID: 35475457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. lncRNA AFAP1-AS1 Promotes Migration and Invasion of Non-Small Cell Lung Cancer via Up-Regulating IRF7 and the RIG-I-Like Receptor Signaling Pathway.
    Tang XD; Zhang DD; Jia L; Ji W; Zhao YS
    Cell Physiol Biochem; 2018; 50(1):179-195. PubMed ID: 30278439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA RGMB-AS1 inhibits HMOX1 ubiquitination and NAA10 activation to induce ferroptosis in non-small cell lung cancer.
    Gao GB; Chen L; Pan JF; Lei T; Cai X; Hao Z; Wang Q; Shan G; Li J
    Cancer Lett; 2024 May; 590():216826. PubMed ID: 38574881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.